Global Active Pharmaceutical Ingredients/API Market

1 INTRODUCTION OF GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/APIMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/APIMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/API MARKET, BY THERAPEUTIC APPLICATION:
5.1 Oncology
5.2 Cardiovascular Disease
5.3 Diabetes
5.4 Central Nervous System and Neurological Disorders
5.5 Endocrinology
5.6 Other Therapeutic Applications

6 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/API MARKET, BY TYPE OF DRUG:
6.1 Prescription Drugs
6.2 Over-The-Counter Drugs
6.3 Active Pharmaceutical Ingredients Market, By Potency
6.3.1 Low to Moderate Potency Active Pharmaceutical Ingredients
6.3.2 Potent to Highly Potent Active Pharmaceutical Ingredients

7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/API MARKET, BY TYPE OF SYNTHESIS:
7.1 Synthetic Active Pharmaceutical Ingredients
7.1.1 Innovative Synthetic APIs
7.1.2 Generic Synthetic APIs
7.2 Biotech Active Pharmaceutical Ingredients
7.2.1 By Type
7.2.1.1 Innovative Biotech APIs
7.2.1.2 Biosimilars
7.2.2 By Product
7.2.2.1 Monoclonal Antibodies
7.2.2.2 Vaccines
7.2.2.3 Hormones and Growth Factors
7.2.2.4 Cytokines
7.2.2.5 Fusion Proteins
7.2.2.6 Therapeutic Enzymes
7.2.2.7 Blood Factors
7.2.3 By Expression System
7.2.3.1 Mammalian Expression Systems
7.2.3.2 Microbial Expression Systems
7.2.3.3 Yeast Expression Systems
7.2.3.4 Plant Expression Systems
7.2.3.5 Insect Expression Systems

8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/API MARKET, BY TYPE OF MANUFACTURER:
8.1 Captive Manufacturers
8.2 Merchant API Manufacturers

9 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/API MARKET, BY TYPE:
9.1 Innovative Active Pharmaceutical Ingredients
9.2 Generic Active Pharmaceutical Ingredients

10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/APIMARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

11 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS/APIMARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 Pfizer, Inc.
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 Novartis International AG
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 Sanofi
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 BoehringerIngelheim
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 Bristol-Myers Squibb
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Teva Pharmaceutical Industries Ltd.
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 ELI Lilly and Company
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 Glaxosmithkline PLC
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 Merck & Co., Inc.
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Development

12.10 Abbvie Inc.
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Development

13 Appendix
13.1 Related Reports